西班牙马德里2022年5月至8月猴痘疫情期间暴露后疫苗有效性与接触者管理
研究对马德里2022年5月17日至8月15日确诊猴痘病例的484名密切接触者进行前瞻性队列生存分析,随访至49天。230人在暴露后14天内接种第三代天花疫苗,57人发病(接种者8人、未接种者49人)。调整后疫苗有效性为88.8%(95%CI:76.0-94.7);性接触者中非同居者93.6%(95%CI:72.1-98.5),同居者88.6%(95%CI:66.1-96.2)。
要点
- 密切接触者暴露后14天内接种第三代天花疫苗的调整有效性为88.8%(95%CI:76.0-94.7)。
- 性接触者中非同居者疫苗有效性93.6%(95%CI:72.1-98.5),同居者88.6%(95%CI:66.1-96.2)。
- 57名发病接触者中8人已接种、49人未接种,暴露后预防可减少病例数。
核心结论
- 对猴痘病例密切接触者进行暴露后预防是有效措施,可有助于减少病例数并最终减轻突破感染的症状。
- 持续使用暴露后预防联合暴露前预防接种及其他针对人群的预防措施是控制猴痘疫情的关键因素。
研究设计与样本
- 前瞻性队列生存分析,纳入2022年5月疫情开始以来马德里地区实验室确诊猴痘病例的密切接触者。
- 研究对象为该地区2022年5月17日至8月15日诊断病例的接触者,随访至49天。
- 采用多因素比例风险模型评估存在混杂和交互作用时的疫苗有效性。
主要发现
- 共获得484名密切接触者信息,其中230人在暴露后14天内接种疫苗。
- 随访期间57名密切接触者发病,其中接种者8人、未接种者49人。
- 疫苗调整后有效性为88.8%(95%CI:76.0-94.7)。
- 性接触者中非同居者疫苗有效性为93.6%(95%CI:72.1-98.5),同居者为88.6%(95%CI:66.1-96.2)。
关键数值与推荐
- 暴露后14天内接种一剂第三代天花疫苗的调整疫苗有效性为88.8%(95%CI:76.0-94.7)。
- 性接触者中非同居者疫苗有效性93.6%(95%CI:72.1-98.5),同居者88.6%(95%CI:66.1-96.2)。
临床怎么用
- 对猴痘病例密切接触者在暴露后14天内接种第三代天花疫苗可作为暴露后预防措施。
- 控制猴痘疫情需持续采用暴露后预防联合暴露前预防接种及其他针对人群的预防措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundAppropriate vaccination strategies have been key to controlling the outbreak of mpox outside endemic areas in 2022, yet few studies have provided information on mpox vaccine effectiveness (VE).AimTo assess VE after one dose of a third-generation smallpox vaccine against mpox when given as post-exposure prophylaxis (PEP) within 14 days.MethodsA survival analysis in a prospective cohort of close contacts of laboratory-confirmed mpox cases was conducted from the beginning of the outbreak in the region of Madrid in May 2022. The study included contacts of cases in this region diagnosed between 17 May and 15 August 2022. Follow up was up to 49 days. A multivariate proportional hazard model was used to evaluate VE in the presence of confounding and interaction.ResultsInformation was obtained from 484 close contacts, of which 230 were vaccinated within 14 days of exposure. Of the close contacts, 57 became ill during follow-up, eight vaccinated and 49 unvaccinated. The adjusted effectiveness of the vaccine was 88.8% (95% CI: 76.0-94.7). Among sexual contacts, VE was 93.6% (95% CI: 72.1-98.5) for non-cohabitants and 88.6% (95% CI: 66.1-96.2) for cohabitants.ConclusionPost-exposure prophylaxis of close contacts of mpox cases is an effective measure that can contribute to reducing the number of cases and eventually the symptoms of breakthrough infections. The continued use of PEP together with pre-exposure prophylaxis by vaccination and other population-targeted prevention measures are key factors in controlling an mpox outbreak.
引用
- Montero Morales L, Barbas Del Buey JF, Alonso García M, et al. Post-exposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022. Euro Surveill. 2023. PMID: 37318762. doi:10.2807/1560-7917.ES.2023.28.24.2200883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。